GlaxoSmithKline announced Wednesday that Swissmedic approved breast cancer drug, Tyverb (lapatinib). The company noted that, subject to regulatory approval, it remains on track to launch the treatment in the rest of Europe in the second half of the year.
Tyverb is indicated in Switzerland to treat advanced or metastatic HER2-positive breast cancer, in combination with Roche's Xeloda in patients who have received prior therapy with Roche's Herceptin. The drugmaker added that preliminary data from a late-stage study suggest the compound may help decrease the development of brain metastases as the site of first relapse in patients with HER2-positive breast cancer, and studies are being carried out to confirm this finding.
In March, the treatment received regulatory approval in the US, where it is marketed as Tykerb.
To read more Top Story articles, click here.